A Real-world Study in Participants With Smoldering Multiple Myeloma

Inclusion Criteria:

• Have a documented diagnosis of smoldering multiple myeloma (SMM). SMM is defined as: (a) Clonal bone marrow plasma cells (BMPCs) greater than or equal to (>=) 10 percent (%) and/or serum M-protein >= 3 grams per deciliter (g/dL) and/or urine M-protein >= 500 milligram per 24 hours (mg/24hrs). (b) Absence of SLiM-CRAB criteria: >= 60 %clonal BMPCs, involved/uninvolved free light chain (FLC) ratio >= 100 and involvedFLC >= 10 and magnetic resonance imaging (MRI) lesions; calcium elevation, renalinsufficiency, anemia, and bone lesions (AB) criteria

• Informed consent obtained prior to retrospective data collection in accordance withlocal requirements, either an informed consent form (ICF) indicating that theparticipants signed a consent for data collection for this research and agrees tohave their data collected and analyzed, with source data verification (SDV), or thecountry does accept the ICF waiver for such type of studies

• Data recorded in participants' medical charts from date of SMM diagnosis and atleast 2 years after should be available in the participant's medical chart at theparticipating site. However, participants who died within the 2 years from SMMdiagnosis are eligible

Exclusion Criteria:

• Therapy for multiple myeloma (MM) initiated within 90 days of SMM diagnosis

• Date of SMM diagnosis is missing

• Participants who have participated/are participating in any SMM interventional (either active treatment or control arm) study are not eligible. Participation inobservational studies is allowed. Participants who have participated/areparticipating in any MM study after evolution to MM are eligible